53P Novel ex-vivo manufacturing of transiently expressed armoured CAR T cells for glioblastoma
Year: 2024
Type: article
Abstract: P-MUC1C-ALLO1 cells/kg following LD with cy 1000 mg/m2 and flu 30 mg/m 2 Â 3 days developed G3 CRS (DLT).No DLTs were reported in any other study arms.Conclusions: P-MUC1C-ALLO1 is an "off-the-shelf" allogeneic CAR-T with a manageable toxicity profile in heavily pre-treated solid tumor patients.Updated safety and efficacy data will be presented at the conference. Clinical trial identification: NCT05239143.Legal entity responsible for the study: Poseida Therapeutics Inc.
Source: Immuno-Oncology Technology
Authors: S. Srivastava, M. Mangolini, E. Souster, K. Hu, D. Pombal, L. Schultz, Y. Yang, B. Ma, S. Cordoba, S. Onuoha
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,170
OpenAlex ID: W4405375173